Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ...

By Yahoo! Finance | Nov 13, 2024 at 02:11 AM EST

The proposed phase two study targets patients with two prior lines of chemotherapy containing platinum. Patients must have received maintenance with Bevacizumab or Parp inhibitors but not suitable for further maintenance therapy with these drugs, primarily focusing on third-line patients.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.